Migraine history and response to lasmiditan across racial and ethnic groups

References

• Dodick DW. Migraine. Lancet. 2018;391(10127):1315–1330.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300–1311.
   PubMed Web of Science ®Google Scholar
• Loder S, Sheikh HU, Loder E. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. Headache. 2015;55(2):214–228.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology. 1996;47(1):52–59.
   PubMed Web of Science ®Google Scholar
• Nicholson RA, Rooney M, Vo K, et al. Migraine care among different ethnicities: do disparities exist? Headache. 2006;46(5):754–765.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Loder E, Diamond S, et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27(3):220–229.
   PubMed Web of Science ®Google Scholar
• Heckman BD, Holroyd KA, Tietjen G, et al. Whites and African-Americans in headache specialty clinics respond equally well to treatment. Cephalalgia. 2009;29(6):650–661.
   PubMed Web of Science ®Google Scholar
• committee Iom. Unequal treatment: confronting racial and ethnic disparities in health care. Washington (DC): National Academies Press (US) Copyright 2002 by the National Academy of Sciences. All rights reserved.; 2003. (Smedley BD, Stith AY, Nelson AR, editors. Unequal treatment: confronting racial and ethnic disparities in health care).
   Google Scholar
• Charleston IL, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018;38(5):876–882.
   PubMed Web of Science ®Google Scholar
• Burke-Ramirez P, Asgharnejad M, Fau-Webster C, et al. Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: a comparison between ethnic groups. Headache. 2001;41(9):873–882.
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159–1169.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97.
   PubMed Web of Science ®Google Scholar
• Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action - review of a selective 5-HT(1F) agonist. J Headache Pain. 2020;21(1):71–13.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine. Neurology. 2018;91(24):e2222–e2232.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019; Jul 1142(7):1894–1904.
   PubMed Web of Science ®Google Scholar
• Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 2019;39(8):957–966.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-Treat migraine attacks. Headache. 2020;60(8):1601–1615.
   PubMed Web of Science ®Google Scholar
• Garnett T, Fitzgerald J. Four ways drug companies can ease racial disparities Politico2020. Available from: https://www.politico.com/news/agenda/2020/07/20/drug-companies-coronavirus-racial-disparities-372277.
   Google Scholar
• Woods-Burnham L, Johnson JR, Hooker SE, et al. The role of diverse populations in US clinical trials. Med. 2021;2(1):21–24.
   Google Scholar
• IHS. ICHD-II classification: parts 1–3: primary, secondary and other. Cephalalgia. 2004;24(1_suppl):23–136.
   PubMedGoogle Scholar
• IHS. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Collection of race and ethnicity data in clinical trials. Washington: Office of Minority Health; 2016.
   Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2935–2959.
   PubMed Web of Science ®Google Scholar
• Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6–38.
   PubMed Web of Science ®Google Scholar
• Ashina M, Vasudeva R, Jin L, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788–1801.
   PubMed Web of Science ®Google Scholar
• Charleston L. Headache disparities in African-Americans in the United States: a narrative review. J Natl Med Assoc. 2021;113(2):223–229.
   PubMed Web of Science ®Google Scholar
• Charleston L, Spears RC, Flippen C, 2nd. Equity of African American men in headache in the United States: a perspective from African American headache medicine specialists (part 1). Headache. 2020;60(10):2473–2485.
   PubMedGoogle Scholar
• Ortega AN, Roby DH. Ending structural racism in the US health care system to eliminate health care inequities. JAMA. 2021;326(7):613–615.
   PubMed Web of Science ®Google Scholar
• Bailey ZD, Feldman JM, Bassett MT. How structural racism works - racist policies as a root cause of U.S. racial health inequities. N Engl J Med. 2021;384(8):768–773.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.
   PubMed Web of Science ®Google Scholar
• Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a Meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8(3):e020498.
   PubMed Web of Science ®Google Scholar
• Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296(3):283–291.
   PubMed Web of Science ®Google Scholar
• Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.
   PubMed Web of Science ®Google Scholar
• Becker C, Brobert GP, Almqvist PM, et al. Migraine and the risk of stroke, TIA, or death in the UK (CME). Headache. 2007;47(10):1374–1384.
   PubMed Web of Science ®Google Scholar
• Sacco S, Ornello R, Ripa P, et al. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol. 2015;22(6):1001–1011.
   PubMed Web of Science ®Google Scholar
• Peng KP, Chen YT, Fuh JL, et al. Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia. 2017;37(4):327–335.
   PubMed Web of Science ®Google Scholar
• Adelborg K, Szépligeti SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96.
   PubMed Web of Science ®Google Scholar
• Buse DC, Reed ML, Fanning KM, et al. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(1):31–44.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltran E, Labastida-Ramirez A, Van den Bogaerdt A, et al., editors. In vitro characterization of agonist binding and functional activity at a panel of serotonin receptor subtypes for lasmiditan, triptans and other 5-HT receptor ligands and activity relationships for contraction of human isolated coronary artery. Cephalalgia. 2017;37:363.
   Google Scholar
• Beltran ER, Kristian H, Labastida A, et al., editors. Lasmiditan and sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro contraction of human arteries. Cephalalgia. 2016;36:104–105.
   Google Scholar
• James SA. John Henryism and the health of African-Americans. Cult Med Psychiatry. 1994;18(2):163–182.
   PubMed Web of Science ®Google Scholar
• Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005;45(5):538–545.
   PubMed Web of Science ®Google Scholar
• Golden W, Evans JK, Hu H. Migraine strikes study: factors in patients’ decision to treat early. J Headache Pain. 2009;10(2):93–99.
   PubMed Web of Science ®Google Scholar
• Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19–27.
   PubMed Web of Science ®Google Scholar
• Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.
   PubMedGoogle Scholar
• Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20(9):765–786.
   PubMed Web of Science ®Google Scholar
• Friesen P, Blease C. Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection. J Med Ethics. 2018;44(11):774–781.
   PubMed Web of Science ®Google Scholar
• Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015;156(12):2616–2626.
   PubMed Web of Science ®Google Scholar
• Milani SA, Swain M, Otufowora A, et al. Willingness to participate in health research among community-dwelling middle-aged and older adults: does race/ethnicity matter? J Racial Ethn Health Disparities. 2021;8(3):773–782.
   PubMed Web of Science ®Google Scholar
• Tuckson RV. The disease of distrust. Science. 2020;370(6518):745.
   PubMed Web of Science ®Google Scholar